The first and only clinically proven laser treatment to delay AMD progression from its early stages to Geographic Atrophy or Wet AMD, 2RTTM demonstrated a 77% reduction in the rate of progression to late-stage disease in 76% of high-risk intermediate AMD patients.*
* Post hoc analysis of intermediate AMD patients without coexistent reticular pseudodrusen (RPD) and no signs of atrophy. Published data available upon request.
Every day, Ellex collaborates with leading physicians, teaching institutions and universities to discover, develop and deliver new technologies for the safe and effective treatment of a broad range of eye conditions.
Since 1985, we've made it our mission to invest in the healing power of ophthalmic laser technology and help to transform the sight and the lives of people across the globe.
Today, more than 35,000 Ellex ophthalmic laser and ultrasound systems, along with iTrack™ — our solution for minimally invasive glaucoma surgery — are in use in over 100 countries around the world, achieving ophthalmic outcomes once never thought possible — safely, effectively, accurately and consistently.